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ID4 controls mammary stem cells and marks
breast cancers with a stem cell-like phenotype
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Basal-like breast cancer (BLBC) is a heterogeneous disease with poor prognosis; however, its
cellular origins and aetiology are poorly understood. In this study, we show that inhibitor of
differentiation 4 (ID4) is a key regulator of mammary stem cell self-renewal and marks a
subset of BLBC with a putative mammary basal cell of origin. Using an ID4GFP knock-in
reporter mouse and single-cell transcriptomics, we show that ID4 marks a stem cell-enriched
subset of the mammary basal cell population. ID4 maintains the mammary stem cell pool by
suppressing key factors required for luminal differentiation. Furthermore, ID4 is specifically
expressed by a subset of human BLBC that possess a very poor prognosis and a transcrip-
tional signature similar to a mammary stem cell. These studies identify ID4 as a mammary
stem cell regulator, deconvolute the heterogeneity of BLBC and link a subset of mammary
stem cells to the aetiology of BLBC.
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T
he mammary gland offers a unique model for the study of
epithelial stem cell biology and differentiation pathways
since the majority of its development occurs after birth.
At birth the mammary gland is composed of only a rudimentary
ductal epithelial structure, and then fully develops during puberty
and pregnancy1. The mature virgin mammary gland is composed
of a bilayered ductal structure, comprised of two main terminally
differentiated cell types, the inner luminal cell layer surrounded
by a myoepithelial cell layer. Within the mammary epithelium
there are marked proliferative bursts at puberty and during
pregnancy requiring an increase in the stem/progenitor cell pool
followed by rapid cell proliferation and differentiation. During
pubertal development the terminal end buds (TEBs) are sites of
massive tissue remodelling and are enriched for stem cell
activity2,3.
Investigation of the molecular mechanisms controlling
mammary epithelial lineage commitment has led to the
elaboration of a network of transcriptional pathways promoting
luminal fate specification and terminal differentiation. Some of
the earliest cell fate decisions within the mammary epithelial stem
cell may be controlled by the Notch and Hedgehog pathways to
promote luminal differentiation4,5. The subsequent activation of
transcription factors GATA-binding protein 3 (Gata3), breast
cancer type-1 susceptibility protein (Brca1), E74-like factor 5
Elf-5 (Elf5) and Forkhead box protein M1 (FoxM1) and Notch
signalling are required for luminal progenitor cell fate and then
terminal ductal/alveolar luminal cell differentiation6–10. In
contrast, the transcriptional regulators of stem cell maintenance
and myoepithelial cell differentiation are poorly described, in part
due to the difficulties in purifying stem cells from myoepithelial
cells for transcriptional and biochemical characterization11,12. On
the basis of expression of cell surface antigens CD24 and CD29 or
CD49f13,14, stem cells capable of reconstituting mammary glands
in vivo can only be isolated to a purity ofB1–5%, the remainder
comprising myoepithelial cells. It is established that Wnt
signalling is necessary for mammary stem cell (MaSC)
maintenance11, and that the expression of transcription factors
Slug and Sox9 is sufficient to reprogramme the stem cell state
from luminal epithelial cells15.
Transcriptional profiling of the mixed ‘basal cell’ population
reveals specific expression of many genes compared with luminal
progenitors or committed luminal cells, with the helix-loop-helix
(HLH) transcription factor inhibitor of differentiation 4 (ID4),
one of the highest among these genes in both the human and
murine basal population16. Id proteins regulate stem cell
homeostasis and fate commitment in various cell types,
including neuronal17, hematopoietic18,19 and embryonic20 cells.
The role of the Id proteins has been studied to a limited extent in
mammary gland development. Id1 is unnecessary for mammary
gland development21, whereas Id2 is necessary for normal RANK
signalling within the mammary gland22. Id4 loss leads to a delay
in pubertal mammary gland development, associated with an
increase in p38MAPK phosphorylation; however, this study
did not identify a direct molecular link between Id4
as a transcriptional regulator and changes in p38MAPK
phosphorylation nor did it address the role of Id4 in mammary
epithelial fate decisions23.
Studies of mammary development have led to great insights
into breast cancer biology, and it is now clear that a number of
transcription factors controlling luminal lineage commitment,
such as Gata3 and Brca1, are potent breast tumour suppressors,
frequently mutated in malignancy6,7,10,24. Breast cancer is a
heterogeneous disease, with at least five major subtypes
distinguished by unique clinical behaviour, molecular
signatures, genomic features and histopathology25. The basal-
like breast cancer (BLBC) subtype comprises B18% of all breast
cancer diagnoses and is associated with early age of diagnosis,
high grade and early relapse26,27. Considerable heterogeneity in
gene expression and clinical prognosis exists within the BLBC
subtype, where B30–50% of patients relapse within 3–5 years
while the remaining patients have good long-term survival
(reviewed in ref. 28). Thus markers that can stratify survival in
this subtype of breast cancer are of particular clinical significance.
There is increasing evidence that the different subtypes of breast
cancer are derived from different cells of origin within the stem
cell hierarchy. Due to the frequent expression of basal
cytokeratins by BLBC, the cell of origin for BLBC was initially
thought to be a basal stem or myoepithelial cell. More recent
molecular profiling of BLBC suggests luminal progenitors as the
cell of origin for BLBCs in BRCA1 mutation carriers29,30,
although the generality of this finding across the diversity of
sporadic BLBC is not yet clear.
In this study, we provide evidence that ID4 is a key controller
of mammary stem/progenitor cell self-renewal, acting upstream
of Notch signalling to repress luminal fate commitment. ID4 is
overexpressed and required by a subset of BLBCs, and patients
with ID4þ BLBCs have particularly poor prognosis and a
stem-like transcriptional profile.
Results
Id4 expression is enriched in MaSCs. We detected Id4
immunoreactivity within the nuclei of the basal cell layer of
mammary glands, including the cap cells and some body cells of
the TEBs of the pubertal gland (Supplementary Fig. 1a).
Co-immunofluorescence demonstrated that Id4 co-localized with
the basal cell marker p63 but not with the luminal cell marker
cytokeratin 8 (CK8) (Supplementary Fig. 1b). Basal cells in the
duct showed heterogeneous expression of Id4 (Supplementary
Fig. 1b), with particularly high expression, when compared with
ductal basal cells, in the cap cells of TEBs of pubertal mice
(Fig. 1a), a location previously reported to be enriched for
mammary stem and progenitor cells2,3. The exclusive expression
of Id4 within the basal cell population was confirmed using adult
mice heterozygous for an enhanced green fluorescent protein
(EGFP) allele knocked into the Id4 locus, which have previously
been used to show an important role for Id4 in neural stem cell
maintenance31. EGFP expression was analysed in the mammary
epithelial basal (CD24þ , CD29hi and CD61þ ), luminal
progenitor (CD24þ ,CD29lo and CD61þ ) and mature luminal
(CD24þ , CD29lo and CD61 ) subpopulations by flow
cytometry6. EGFP expression was restricted to the basal
compartment, where B16% of basal cells highly expressed
EGFP (Fig. 1b). To determine whether Id4hi cells within the basal
compartment were enriched for stem cell activity, we
transplanted CD29hi EGFPhi and CD29hi EGFPlo basal cells at
two doses (100 and 500 cells) into the contralateral glands of
3-week-old FVB/N mice that had undergone surgical clearing of
endogenous mammary epithelium. After 8 weeks, EGFPhi cells
had engrafted to form mammary ductal trees at a significantly
greater frequency at both cell doses, with an overall sevenfold
increase in the proportion of mammary repopulating units
(MRUs) in the Id4 EGFPhi cells than the Id4 EGFPlo cells
(P¼ 0.005) (Fig. 1c; Supplementary Table 1).
To further explore the biology of Id4hi basal cells at a cellular
level, we used the murine mammary Comma-D cell line model
that has been used previously to analyse mammary stem and
progenitor cells32–34. When transplanted into the cleared fat pads
of syngenic BALB/c mice, Comma-D cells formed relatively
normal mammary outgrowths composed of bilayered ducts
with Id4-positive basal cells and Id4-negative luminal cells
(Supplementary Fig. 1c,d), suggesting a functional mammary
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Figure 1 | Identification and functional characterization of Id4-positive MECs. (a) Id4 and cytokeratin 8 (CK8) expression detected by
immunofluorescence in terminal end buds (upper panels) and mature ducts (lower panels) of 8-week-old wild-type mice. Scale bars, 20 mm. Representative
image from five animals analysed. (b) Id4GFP reporter activity in MEC subsets identified by CD24, CD29 and CD61 immunostaining and flow cytometry.
Representative histograms from five independent experiments. (c) Sorted CD29hi/GFPhi and CD29hi/GFPlo mammary epithelium from Id4GFP/þ mice
were transplanted at two doses (100 and 500 cells) into the cleared mammary fat pad of naive FVB/N mice (seven glands per group) and analysed by
whole-mount histology 8 weeks later. Percentage of transplanted mammary glands that showed a positive engraftment indicated below. Scale bars, 1mm.
(d) Single-cell RT–PCR for Id4 and MEC differentiation markers in Id4hi (top quartile; red) and Id4lo (bottom quartile; green) cells. All genes with
significantly altered expression are shown with P value (ANOVA). * Indicates a negative correlation.
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epithelial lineage hierarchy exists within these cells. When cultured
in vitro, Comma-D cells maintain a heterogeneous mixture of cells
with basal and luminal features, including cells with diverse
expression of Id4 as observed in vivo (Supplementary Fig. 1e). We
used single-cell multiplexed reverse transcriptase (RT)–PCR to
study the gene expression of unsorted Comma-D cells to gain an
insight into whether Id4hi cells possessed a MaSC signature. Using
integrated microfluidic chambers, 166 individual Comma-D cells
were analysed for expression of 92 genes of interest and 3
housekeeping genes. Selected genes included markers of mammary
basal, progenitor and differentiated cells13,14,35,36, and common
epithelial markers (Supplementary Data 1). Confirming our
observation by immunofluorescence (IF) (Supplementary
Fig. 1e), Id4 messenger RNA (mRNA) was also heterogeneously
expressed, while housekeeping genes were consistently expressed
by all cells (Supplementary Fig. 2). Unsupervised clustering showed
that Id4 associated with the expression of other Id proteins and
markers of stem and basal cells such as Sox9 (Supplementary
Fig. 2). To determine the genes with which Id4 was statistically
significantly associated, gene expression of the top and bottom
quartile Id4-expressing cells was analysed and visualized using
violin plots (Fig. 1d) or using box plots (Supplementary Fig. 3). Id4
expression was significantly correlated with high expression of the
canonical basal and MaSC markers Itga6 (CD49f13) and Itgb1
(CD29; ref. 14) and with other Id family members Id1, Id2 and Id3.
Id4 expression also positively correlated with 7 of 22 markers of
fetal MaSC (fMASC) morphogenesis (CD24a, Sfrp1, Foxc1, Fzd6,
Trpv6, Cryab and Kctd14) (Fig. 1d), previously shown to be
elevated in poor prognosis BLBC36. In contrast, Id4 was not
associated with any of the seven markers of luminal differentiation
analysed, such as the oestrogen receptor and Gata3. The gene most
robustly positively associated with Id4 expression was Sox9
(approximately fourfold higher in Id4þ cells; Po10 5), a
master regulatory transcription factor required and sufficient for
MaSC activity15. In contrast, Id4 was strongly negatively correlated
with FoxM1 (B15-fold lower in Id4þ cell; Po10 5), a
transcriptional repressor highly expressed in, and required by,
luminal progenitors10. Together, these results demonstrate that Id4
expression is localized to regions of stem cell activity, that cells
expressing Id4 are enriched for stem cell activity and that there is a
stem-like gene expression programme in Id4hi cells with
similarities to adult and fetal stem cell signatures.
Id4 is required for mammary ductal morphogenesis. To further
understand Id4’s functional role in mammary development, we
examined ductal elongation and ductal morphogenesis in the
mammary glands of 8-week-old adult Id4 / mice. Whole-
mount histology showed that Id4 / glands were poorly
developed, with a fourfold reduction in the area of fat pad filled at
8 weeks of age (Fig. 2a). These results confirm the findings
of Dong et al.23 that Id4 is critical for ductal elongation.
To determine whether this phenotype was caused by a cell-
autonomous stem cell defect, we transplanted Id4 / mammary
epithelial cells (MECs) into the cleared mammary fat pad of wild-
type recipients at limiting dilutions. These experiments revealed a
reduction in the frequency of MRUs in Id4 / mammary glands
compared with controls with a 46% reduction in the frequency of
MRUs in the Id4 / glands (P¼ 0.025) (Table 1). Furthermore,
in glands where engraftment did occur, there was a B50%
reduction in the extent of ductal invasion (Fig. 2b). Interestingly,
there was no reduction in the proportion of total basal cells
in the Id4 / glands when compared by flow cytometry
(Supplementary Fig. 4a,b). This may be due to compensatory
upregulation of Id1 and Id3 in the Id4 null glands
(Supplementary Fig. 4c). To further validate the necessity of a
cell intrinsic role for Id4 in epithelial homeostasis, we analysed
Id4 knockdown by two independent short hairpin RNA (shRNA)
in Comma-D cells (Fig. 2c); these led to a significant inhibition of
proliferation in vitro (Po0.0002, two-way analysis of variance
(ANOVA), n¼ 3) (Fig. 2d).
Id4 is a key controller of luminal differentiation pathways.
Given that Id4 was highly expressed in mammary basal cells yet
undetectable in luminal epithelium (Fig. 1b) and that Id4
expression was required for normal MaSC activity, we asked
whether Id4 was sufficient to prevent luminal differentiation of
mammary epithelial stem cells. The Comma-D cell line model
undergoes luminal differentiation over a 4-day time course of
confluence and growth factor withdrawal. Overexpression of Id4
did not alter proliferation of Comma-D cells in this assay
(Supplementary Fig. 5a), but did upregulate constitutive cyto-
keratin 14 expression and markedly inhibited terminal luminal
cell differentiation as measured by milk protein production and
CK8 expression (Supplementary Fig. 5b,c). The inhibition of milk
protein production by Id4 overexpression confirm the findings of
Shan et al.37 in the related HC11 cell line.
To determine the mechanism by which Id4 controls luminal
commitment of MaSCs, we examined expression of Brca1, Elf5
and activation of the Notch pathway, all of which are required for
appropriate luminal epithelial commitment by MaSCs5,8,9. Id4
overexpression reduced constitutive expression of the luminal
progenitor marker Brca1 (Fig. 3a). Under differentiation
conditions, Comma-D cells upregulate Elf5 expression and
Notch signalling as measured by an approximately ninefold
increase in expression of the Notch target gene Hey1, and these
increases were markedly inhibited by Id4 overexpression (Fig. 3a).
In addition, gene expression analysis of Id4 / mammary
glands revealed a marked increase in the expression of Notch
pathway genes Hey1, Notch1 and Jag1 (Fig. 3b), consistent with a
role for Id4 in suppressing Notch pathway activity.
To test whether the observed reduction in Notch signalling was
sufficient to account for the inhibition of luminal differentiation by
Id4 overexpression, we treated Comma-D cells with DAPT (N-[N-
(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester), a
gamma-secretase inhibitor that prevents Notch receptor cleavage
and activation38. DAPT treatment phenocopied Id4 overexpression
by suppressing the induction of Hey1, cytokeratin 8 and Elf5
expression through the time course of in vitro differentiation
(Fig. 4a,b). Unlike Id4 overexpression, DAPT treatment did not
inhibit expression of Brca1 (Fig. 4c) and only partially suppressed
b-casein expression when compared with Id4 overexpression
(Fig. 4c versus Supplementary Fig. 5c). Id4 was previously
suggested to regulate mammary epithelial proliferation through
suppression of p38MAPK activity, as determined by p38MAPK
phosphorylation23. However, overexpression of Id4 in Comma-D
cells did not suppress, nor did Id4 knockdown enhance, the
expression of total or phospho-p38MAPK (Supplementary Fig. 6).
ID4 expression marks a subset of BLBC with poorer prognosis.
As the factors controlling luminal commitment, such as Brca1 and
Elf5 also have well-characterized roles in breast cancer aetiol-
ogy29,39,40, we next looked at the role ID4 may play in breast
cancer. ID4 protein expression in a discovery cohort of 74 breast
cancers was largely restricted to ER-negative cases, where it
displayed a bimodal pattern of either no staining or strong staining
in a majority of cells as seen in 46% of cases (Fig. 5a,b). ID4mRNA
followed a similar pattern of expression within the Cancer Genome
Atlas (TCGA) data set41, with the highest expression in the normal
samples and a wide range of ID4 expression observed in the BLBC
subtype based on PAM50 classification (Supplementary Fig. 7a).
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To test whether ID4 is important to the biology of ID4þ BLBCs,
we knocked down ID4 expression in the MDA-MB-468 BLBC cell
line model. Two independent shRNA constructs targeting ID4
significantly reduced proliferation in vitro (Po0.0001, two-way
ANOVA, n¼ 3) (Fig. 5c). In addition, ID4 knockdown markedly
reduced the growth of MDA-MB-468 xenografts in vivo
(Supplementary Fig. 7b). It was further confirmed that ID4
knockdown inhibited proliferation of the HCC1806 cell line model
of BLBC (Supplementary Fig. 7c–e).
We then asked whether ID4þ BLBCs have a unique clinical
phenotype. BLBC is characterized by heterogeneous prognosis,
with 30–50% of patients dying of disease within the first 5 years.
Immunohistochemistry (IHC) analysis of ID4 expression in a
cohort of 80 BLBCs revealed that ID4þ BLBC had a very poor
prognosis (hazard ratio 4.24, Po0.0008), with 55% dying of
disease within 3 years of diagnosis (Fig. 5d). In contrast, only 15%
of ID4 BLBCs died of their disease in this period. Interestingly,
the association of ID4 with poor prognosis was independent of
tumour grade or proliferative index (Ki67). ID4 mRNA expression
also predicted poor prognosis in two independent cohorts of
BLBC; 60 BLBCs within the NKI-295 set (P¼ 0.031) and 285 cases
in a compendium of BLBC analysed using the 2014 version of the
online analysis tool KM-Plotter42 (P¼ 0.0029; Supplementary
Fig. 7f,g). Thus ID4 is highly expressed in B50% of all BLBCs
where it associates with very poor prognosis, and controls in vivo
and in vitro proliferation of models of this disease.
ID4 marks a subset of BLBC resembling MaSCs. The luminal
progenitor is thought to be the cell of origin for BLBC, based in
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Figure 2 | Impact of Id4 deficiency on ductal morphogenesis and proliferation. (a) Whole-mount staining of Id4þ / and Id4þ /þ mammary glands at 8
weeks of age. Graphs indicate the mean±s.e.m. Id4þ / n¼8, Id4 / n¼ 7. ***Po0.0005, unpaired t-test. Scale bars, 1mm. (b) Analysis of the ability
of epithelium from Id4 / and Id4þ / mice to fill a mammary fat pad. Graphs indicate the mean±s.e.m. Id4þ / n¼ 6, Id4 / n¼ 5. *Po0.05,
unpaired t-test. Scale bars, 1mm. (c) Western blot following Id4 knockdown by two independent shRNA (shId4 #1 and shId4 #2) compared with a
scrambled control (shCont) and GFP-transduced Comma-D cells (for full western blot see Supplementary Fig. 9). (d) Proliferation assays by cell counting
following Id4 knockdown using two independent shRNA constructs and two independent controls (shControl and shGFP). (n¼ 3 independent experiments)
**Po0.0002, two-way ANOVA.
Table 1 | Limiting dilution analysis of the mammary
repopulating frequency of unsorted mammary epithelial
cells from Id4þ / and Id4 / mice.
Number of cells injected per
mammary fat pad
Number of positive outgrowths
Id4þ / Id4 /
10,000 13/18 10/18
5,000 12/20 10/18
1,000 11/23 3/21
500 0/8 0/8
100 1/15 0/17
Repopulating frequency 1/4923 1/9083
(95% Confidence interval) (1/3404–1/7120) (1/5929–1/13916)
P value 0.025
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Figure 3 | Regulation of pathways controlling luminal fate commitment by Id4. (a) mRNA expression of Brca1 (n¼ 5/group), Elf5 (n¼ 7/group) and
Hey1 (n¼ 7/group) in Comma-D cells over a time course of luminal differentiation in cells overexpressing Id4 or a control. Graphs represent the
mean±s.e.m. (b) mRNA expression of Notch pathway components Hey1, Notch1 and Jag1 in mammary glands from 8-week-old Id4 / mice (n¼4)
compared with controls (n¼ 5). Graphs represent the mean±s.e.m. *Po0.05, **Po0.01, ***Po0.001, unpaired t-test.
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Figure 4 | Expression of differentiation markers following pharmacological Notch pathway inhibition. (a) Expression of notch target gene Hey1 in
Comma-D cells treated with the notch inhibitor DAPTover a time course of confluence. (b) Luminal differentiation as measured by Krt8 and Elf5 expression
following DAPT treatment. (c) Impact of DAPT treatment on Brca1 and Csn2 expression in Comma-D cells. Graphs represent the mean±s.e.m. *Po0.05,
**Po0.01, NS¼ not significant, unpaired t-test. n¼ 5.
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part on the observation that the average transcriptome of BLBC
most resembles the transcriptome of the luminal progenitor29.
Given our earlier finding that ID4 marks a MaSC, we
hypothesized that the ID4-positive subset of BLBCs may
instead resemble a MaSC. To address this hypothesis, BLBC
gene expression in the TCGA cohort was stratified based on the
top and bottom quartile of ID4 expression and differential gene
expression using Limma analysis conducted within these two
groups. Six hundred and seventy-one genes were differentially
expressed (qo0.05) between these groups (Supplementary
Data 2). ID4hi BLBCs were enriched for expression of many
genes characteristic of adult MaSC and/or fetal murine MaSCs;
Itgb1 (1.6-fold), Itga6 (1.9-fold), Sfrp1 (4.9-fold), Wif1 (4.0-fold),
Foxc1 (twofold) and Sox10 (fMaSC, 3.9-fold). Strikingly, the
contractile actin Actg2, previously identified as the most highly
differentially expressed adult mammary basal/stem cell marker by
two independent studies16,43, was elevated 3.5-fold in ID4hi
BLBCs. Two other myoepithelial contractile actins were
upregulated, Acta1 (5.9-fold) and Acta2 (1.7-fold).
To systematically address whether ID4hi BLBC possessed a
stem-like gene expression signature, we took two informatic
approaches. In the first, we used gene-set enrichment analysis
(GSEA) to compare the signature of ID4hi BLBC with 4,722
curated gene sets within the C2 collection of the Molecular
Signatures Database. A large number of gene sets were
significantly associated with the ID4hi BLBC signature, ranked
by their normalized enrichment score. These included a number
of gene sets associated with breast cancer and tissue stem cells.
Interestingly, the 5th most enriched set was the MaSC signature
conserved between human and mouse16, with a very strong
normalized enrichment score of 3.01 (Fig. 6a,b). In contrast, the
mammary luminal progenitor signature showed no statistically
significantly overlap with the ID4hi BLBC signature. In the second
approach, we calculated signature expression scores (SESs) for the
MaSC signature in each molecular subtype of breast cancer (as
described in Lim et al.29), in addition to the ID4hi and ID4lo BLBC
subsets. ID4hi BLBC had a significantly stronger association with
the MaSC signature than either the total BLBC set or the ID4lo
BLBC subset (Fig. 6c). ‘Claudin low’ breast cancers are a molecular
class of triple-negative breast cancers (TNBCs) thought to possess
a mesenchymal- and stem-like gene expression signature44,45 and
are sometimes grouped with BLBC. However, expression of the
definitive claudins 3, 4 and 7 was unchanged between ID4hi and
ID4lo BLBC (Supplementary Data 2), and analysis of ID4
expression in a panel of TNBC cell lines shows no relationship
between ID4 expression and the basal-B mesenchymal-like
phenotype46, nor with the mesenchymal or mesenchymal stem-
like subtypes of TNBC44 (Supplementary Fig. 8).
Discussion
While the mediators of mammary luminal fate commitment have
been extensively described, relatively little is known about the
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mechanisms controlling MaSCs homeostasis. We now report that
Id4 marks a subpopulation of CD24þCD61þCD29hi basal cells
that are enriched for the capacity to repopulate a multi-lineage
mammary epithelial tree. Furthermore, Id4 deficiency depletes
mammary repopulating competency. Id4hi cells were found
distributed throughout the ducts of mature animals and were
abundant in TEBs of pubertal mice, which is in stark contrast to
Lgr5þ MaSCs recently reported to be concentrated near the
nipple and absent from TEBs47. These data suggest the existence
of multiple stem/progenitor populations differing in anatomical
location and development stage.
Using single-cell gene expression profiling, we find that Id4hi cells
possess a gene expression signature related to both adult MaSCs16
and recently identified fMaSCs36, suggesting that these two
populations may not be mutually exclusive. Id4þ cells also
exhibited high expression of Sox9, which is required for MaSC
maintenance and which cooperates with Slug to reprogramme
luminal epithelium into stem cells15. Interestingly, Slug but not Sox9
strongly upregulates ID4 expression15, suggesting that Id4, acting
downstream of Slug, may cooperate with Sox9 in the maintenance
of MaSCs. Although Sox9 was not overexpressed in ID4hi BLBC, its
paralog Sox10 (ref. 48), itself a Sox9 target15, was highly expressed.
Constitutive Id4 overexpression was sufficient to increase the
proportion of basal cells in culture and prevented luminal
commitment under differentiation conditions. Id4 suppressed
expression of key drivers of luminal cell commitment: Brca1, Elf5
and Notch pathway components. Chemical inhibition of Notch
activity using the gamma-secretase inhibitor DAPT did not effect
Id4 expression but phenocopied Id4 overexpression by down-
regulating Notch signalling and preventing luminal commitment,
suggesting that Id4 controls entry into a luminal fate through
Notch inhibition. Interestingly, DAPT treatment, like Id4 over-
expression, also downregulated Elf5 expression, revealing a novel
regulation of Elf5 downstream of Notch signalling. Loss of Elf5 or
Notch signalling is sufficient to prevent luminal differentiation
and for accumulation of MaSCs in vivo5,49, suggesting that
regulation of the Notch–Elf5 axis is a critical target of Id4 in
preventing luminal commitment. Id4 expression, but not DAPT
treatment, inhibited Brca1 expression, indicating that Id4
regulates Brca1 independently of Notch signalling.
Dong et al.23 demonstrated that p38MAPK activity was increased
in the mammary epithelium of Id4 / mice and that inhibiting
p38MAPK could ameliorate some of the proliferative and cell death
phenotypes associated with Id4 deficiency. Our data do not
contradict these findings; however, they suggest that the increased
activity of p38MAPK may be a downstream consequence of
abnormal luminal differentiation. Previous studies have shown that
p38MAPK activity is increased in luminal MECs during pubertal
development and during luminal differentiation in the lung50,51.
BLBCs possess marked molecular and clinical heterogeneity.
While 30–50% of patients die of disease within the first 5 years, the
remaining patients have very good long-term survival. The
discovery of prognostic biomarkers and methods to stratify BLBC
into more homogenous subgroups has been difficult. Our data
show that ID4 is expressed byB50% of BLBCs, with these patients
having far poorer short-term prognosis than ID4low BLBC patients,
thus ID4 may be an important prognostic factor in this subset of
BLBC, especially given the robust IHC test for its expression. While
ID4 expression has previously been associated with TNBCs, we
uniquely report the ability of ID4 to stratify BLBCs into
molecularly or clinically distinct subgroups52–55 and validate its
prognostic significance in two independent data cohorts.
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It has previously been suggested that ID4 is a tumour
suppressor in breast cancer based on methylation of the ID4
promoter being associated with reduced patient survival56,57.
However, neither of these studies discriminated between
molecular or histological subtypes, and BLBC presumably
comprised a minority of the samples in these studies. Indeed,
evidence from the TCGA breast cancer study demonstrates that
luminal B tumours are associated with genome-wide
hypermethylation, whereas luminal A tumours are not26,
leading to the possibility that the observed methylation status
of the ID4 promoter was acting as a surrogate to distinguish the
poorer prognosis luminal B tumours from the better prognosis
luminal A tumours.
BLBCs are currently thought to derive from luminal progeni-
tors, based primarily on the accumulation of luminal progenitors
in BRCA1 mutation carriers at risk of developing BLBC and the
similarity between transcriptional signatures of BLBC and
mammary luminal progenitors29,30. However, these conclusions
are based on assumptions of molecular homogeneity within
BLBC and that BRCA1-mutant BLBC has the same aetiology
as spontaneous BLBC. Our data suggest that BLBCs are
heterogeneous in their aetiology, and that the ID4hi subset
possesses a transcriptional signature more similar to the basal
cell transcriptome than to luminal progenitors, using two
independent informatic approaches. In addition to possessing a
stem cell signature, ID4hi BLBC also expressed high levels of
MaSC markers and contractile actins ACTA1, ACTG2 and
ACTA2, consistent with a basal/myoepithelial phenotype.
There are at least two likely models to explain this observation.
The first is that at some time in these cancers a transformed
luminal progenitor acquired a stem-like state through dediffer-
entiation events, as has been recently observed in a mouse model
of basal cell carcinoma58. The second model is that ID4hi BLBCs
derive from an ID4hi stem or basal progenitor cell and maintain
aspects of the basal phenotype through neoplastic progression,
including a stem-like transcriptome and a dependency on ID4 for
proliferation. There are other examples of this phenomenon,
coined lineage dependency59, perhaps best typified by the
conserved role for the androgen receptor in prostate
development and prostate cancer.
Animal models suggest that either model is possible, as
mutation of Tp53 and Brca1 in luminal progenitors30 or basal
cells60 can generate mammary tumours with features of human
BLBCs. Interestingly, a majority of murine BLBCs derived from
transformation of mammary basal cells express high levels of ID4
ref. 60 as observed in B50% of clinical BLBC cases. When
considered together with our data, these results support the
model that ID4þ BLBCs may have an ID4hi basal cell as their cell
of origin.
Regardless of the cell from which they derive, ID4hi BLBC
clearly have a unique aetiology and hence may require different
clinical management. We predict from the stem-like signature
of these tumours an altered therapeutic response compared
with ID4lo disease. Characterization of the gene expression,
genomic mutations and therapeutic sensitivity of ID4hi BLBC
may offer insights into molecular dependencies in this class of
BLBC and lead to the identification of novel therapeutic
opportunities.
Methods
Mice. All experiments involving mice were performed in an specific-pathogen-free
animal facility in accordance with the ethical regulations of the Garvan Institute
Animal Experimentation Committee. The Id4GFP/GFP mice were generated as
previously described on the C57BL/6 background31. These mice were also
backcrossed five generations onto the FVB/N strain. Wild-type C57BL/6 and
FVB/N mice were also analysed. For xenograft studies, female 8-week-old
NOD.CB17-Prkdcscid/Arc mice were used.
Mammary gland whole mounts and immunostaining. Mammary glands were
dissected and whole-mounted at the indicated ages; these were then fixed in 10%
neutral-buffered formalin overnight, fat was removed with acetone and the ductal
structure was stained with Carmine alum overnight. Glands were then dehydrated
through graded alcohols and imaged under methyl salicylate.
IHC and IF studies were performed on 4-mm sections of formalin-fixed
paraffin-embedded tissue. Antigen retrieval was performed using the DAKO target
retrieval reagent 1699 either for 20min in a boiling waterbath or 1min in a
pressure cooker. The following antibodies were used for IHC and IF analysis,
anti-Id4 (1:400, Biocheck, CA, USA), anti-CK8 (1:500, DSHB, IA, USA), anti-p63
(1:100, Novus Biologicals, CO, USA). Envision anti-rabbit reagent (Dako) and
DAB (Dako) was used to develop the IHC. Scoring of ID4 expression in human
breast cancer samples was scored independently by two individuals based on an
H-score, which is derived by multiplying the staining intensity (0–3) with the
percentage of epithelial cells with positive nuclear staining.
MEC preparations. MECs were prepared from freshly obtained 3rd–5th
mammary glands pooled from 4–10 female 12-week-old FVB/N mice. Mammary
glands were mechanically disrupted with razor blades and then collagenase
digested (Collagenase blend type L, 1mgml 1, Sigma). Epithelial cells were
enriched by two rounds of differential centrifugation, then the mammary
organoinds were further digested with 0.05% trypsin (Invitrogen) followed by
Dispase (Stem Cell Technologies). Cells were passed through a 40-mm cell strainer
and then resuspended as a single-cell suspension in FACS buffer (PBS 2% fetal
bovine serum (FBS) 2% Hepes).
Flow cytometry and FACS. Single-cell suspensions of primary mouse MECs were
incubated with anti-CD16/CD32 antibody (1:200 BD Biosciences) in FACS buffer
to block nonspecific antibody binding. Cells were then pelleted and resuspended in
FACS buffer containing the following lineage markers: anti-CD31-biotin (1:40 BD
Biosciences, Clone: 390), anti-CD45-biotin (1:100 BD Biosciences, Clone:30-F11),
anti-TER119-biotin (1:80 BD Biosciences, Clone: TER119), and anti-BP- biotin
(1:50 eBiosciences, Clone: 6C3) for 20min on ice. Cells were then pelleted
and resuspended in FACS buffer containing streptavidin-APC-Cy7 (1:400 BD
Biosciences) and the following epithelial stem cell markers anti-CD24-PE-Cy7
(1:400, BD Biosciences, Clone: M1/69), anti-CD29-Pacific Blue (1:100 Biolegend
(San Diego, CA, USA), Clone: HMb1-1) and anti-CD61-APC (1:100 Invitrogen,
Clone: HMb1-1), and incubated for 20min on ice. Cells were then washed twice in
FACS buffer before being resuspended in FACS buffer containing DAPI (1:1,000
Invitrogen). Flow cytometry was then performed on a BD LSRII SORP flow
cytometer using BD FACSDIVA software, and the results were analysed using
Flowjo software (Treestar). Sorting was performed on a BD Influx cell sorter using
BD FACSorter software.
Mammary transplants. Single-cell suspensions of primary mouse MECs were
prepared as described above, were resuspended at limiting dilutions in PBS con-
taining magnesium and calcium salts (Gibco/Life Technologies) and then injected
into the cleared 4th mammary gland of 3-week-old female FVB/N recipient mice in
a 10-ml volume using a Hamilton syringe (Reno, NV, USA). Test and control MECs
were injected into contralateral 4th mammary glands. Normal outgrowths were
allowed to form for 8 weeks before the glands were harvested and anaylsed by
whole-mount histology.
Limiting dilution calculations. Limiting dilution analysis of MaSC frequency
were conducted using the ELDA web interface (http://bioinf.wehi.edu.au/software/
elda/)61.
Cell lines. The mouse MEC cell line Comma-Db was a gift from Joseph Jeffery
(University of Massachusetts, Amherst, MA, USA). Comma-Db cells were main-
tained in DMEM/F12 media (Gibco, Grand Island, NY, USA), supplemented with
2% FBS (Thermo-Scientific), 10mM HEPES (Gibco), 5ml penicillin/streptomycin
(Gibco), 0.25% insulin (Novo Nordisk, Bagsvaerd, Denmark) and 5 ngml 1
murine epidermal growth factor (mEGF) (Sigma). MDA-MB-468 cells were
obtained from the American Type Culture Collection and maintained in RPMI
1640 media (Gibco), supplemented with 10% FBS (Thermo-Scientific), 20mM
HEPES (Gibco) and 0.25% insulin (Novo Nordisk). HCC1806 cells were obtained
from the American Type Culture Collection and maintained in RPMI 1640 media
(Gibco), supplemented with 10% FBS (Thermo-Scientific), 20mM HEPES (Gibco)
and 1mM sodium pyruvate (Gibco).
Retroviral transduction of Comma-Db cells. Comma-Db cells (1.1 105) were
seeded into a six-well plate. After 16–24 h, the cells were infected with pMSCV-Id4-
DSred or pMSCV-DSred retrovirus diluted 1:10 in Comma-Db media with
8 mgml 1 polybrene. After 24 h the media was changed. DSred-positive cells were
then FACS enriched using the BD FACSAria fluorescence-activated cell sorter and
BD FACSDIVA software.
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Lentiviral transduction of Comma-Db, MDA-MB-468 and HCC1806 cells.
Cells were seeded into a six-well plate. After 16–24 h, the cells were infected with
lentiviruses expressing shRNA constructs diluted 1:10–1:50 into media with
8 mgml 1 polybrene. After 24 h the media on the cells was replaced with fresh
media. Infection efficiency was determined by fluorescence microscopy on cells
infected with a control lentivirus expressing EGFP (pLV4301).
Lentiviral SMARTchoice Inducible shRNA against Id4 and an irrelevant control
were purchased from Dharmacon. HCC1806 cells were infected with virus at a 1:60
dilution with 8 mgml 1 polybrene and selected with 1 mgml 1 puromycin for
4 days. Cells were treated at time of seeding with doxycyclin at 1 mgml 1, and the
cell proliferation assay started once cells had adhered (6 h post seeding) and
continued for 94 h.
Comma-Db in vitro differentiation. Comma-Db cells were seeded at 0.8 105
cells per well (or for acute lentiviral knockdown studies at 1.1 105 as the infection
process slowed the growth of the cells) into six-well plates; 72 h later, the media was
removed and the cells were washed once with PBS and then media without mEGF
was added to the cells. After 24 h (day 0 of the assay), the media was replaced with
mEGF-free Comma-Db media containing 0.5 mgml 1 prolactin (Sigma) and 1 nM
dexamethasone (Sigma) or fresh mEGF-free media as a control. Media was
replaced daily with fresh media containing prolactin and dexamethasone. RNA and
protein lysates were collected at day 0, day 2 and day 4. Single-cell analysis was
done on cells at the day-2 time point. For the DAPT experiments, 4 mM of DAPT
g-secretase inhibitor (Sigma) or dimethylsulphoxide control was added to the
mEGF-free media on D0. Media was replaced daily with fresh media containing
DAPT or dimethylsulphoxide.
Assay for cell proliferation. MDA-MB-468 cells were seeded at 3.2 103 per well
in a 96-well flat-bottomed plate. On days 0, 1, 2, 3, 4 and 5, following seeding, 20 ml
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt (MTS, Promega) was added to each well and incubated at
37 C in 5% CO2 and 95% air in a tissue culture incubator for 3 h before measuring
absorbance at 490 nm using a FLUOstar Optima plate reader with Optima software
(BMG LabTech). On day 0, cells were allowed to adhere for 4 h before adding MTS
solution. An average of the six replicate wells was taken and the blank absorbance
value was subtracted. All samples were normalized to the day-0 absorbance of the
same cell line and short hairpin construct; that is, on day 4, shID4 23 was nor-
malized to the day-0 shID4 23 absorbance reading.
Relative cell proliferation of HCC1806 cells was calculated using IncuCyte
ZOOM live cell imaging (zoom40061 Essen BioScience).
Xenografts. Surgery was performed as previously described. A total of 1 106
cells were transplanted in 10 ml sterile PBS containing magnesium and calcium
salts. Cells were injected into the fourth thoracic mammary fat pad of 5-week-old
female NOD.CB17-Prkdcscid/Arc mice. Five mice per group (ID4 knockdown and
control cell transplants). Tumour volume was measured twice weekly by a tech-
nician blinded to the identity of mice. Tumours were harvested when control
tumours reached 10mm by the longest diameter.
Western blotting. Protein lysates (5–20 mg) were prepared with 4 loading
buffer (Invitrogen) and sample reducing agent (Invitrogen), denatured by heating
to 70 C for 10min and loaded onto 4–12% bis/tris gels (Invitrogen). Gels were run
at 200V for B40min using MES running buffer (Invitrogen). Proteins from the
gels were then transferred to Hybond ECL nitrocellulose membranes (Amersham
Biosciences, Germany) using the Invitrogen western blotting module and transfer
buffer for 1–1.5 h at 30V. Membranes were then rinsed in TBST and blocked for
1 h at room temperature (or overnight at 4 C) in either TBST 5% skim milk
powder (or TBST 2% BSA for the anti-milk and anti-phospho protein western
blots). Antibodies used for western blotting were anti-Id4 (1:25,000, Biocheck),
anti-Milk proteins (1:10,000, Accurate Chemical & Scientific Corp), anti-p38
MAPK (1:1,000, Cell Signalling), anti-phospho-p38 MAPK (1:1,000 Cell Signalling)
and anti-bActin (1:100,000, Sigma). Western blot bands were visualized using
Western lightning Plus ECL reagent (Perkin Elmer, Waltham, MA, USA) and Fuji
SuperRX film (Tokyo, Japan).
Quantitative RT–PCR. RNA was extracted from cells using either Trizol (Ambion/
Life Technologies) or the RNAeasy Minikit (Qiagen) following the manufacturer’s
instructions. RNA was eluted or resuspended in nuclease-free water (Promega).
RNA was extracted from mammary glands using the RNAeasy Minikit as follows.
20–30mg of snap-frozen mammary gland pieces were ground in microcentrifuge
tubes on dry ice using a 1.5-ml pellet pestle (Lomb Scientific/Thermo-Scientific) for
roughly 10 s until all large pieces are broken up. Six hundred ml of buffer RLT was
added and then the sample was sonicated on ice for a total of 20 s with 2-s pulses
and 0.5-s pauses. RNA extraction was then continued as per the Qiagen RNAeasy
minikit protocol.
Complementary DNA (cDNA) was synthesized from 0.5–1 mg of RNA using
the Superscript III RT–PCR kit (Invitrogen) using oligo-dT primers and following
the manufacturer’s instructions. TaqMan probes (Applied Biosystems/Life
Technologies) were used to analyse mRNA expression levels as per manufactures
specifications (Table 2) using an ABI PRISM 7900 HT machine.
Acquisition of TCGA data. Clinical and molecular annotation of samples was
obtained from the marker TCGA BRCA publication (Supplementary Table 1 in
TCGA Nature 2012, PMID: 23000897). Agilent mRNA expression microarray data
(level 3) was obtained from the TCGA data portal in January 2012. The microarray
data consisted of 8 normal-like, 98 basal-like, 58 Her2-enriched, 231 luminal A and
127 luminal B tumours. Two methods were used for replacing missing expression
values: for GSEA analysis missing values were imputed and replaced using the
k-nearest-neighbour approach, with k¼ 10; for SES analysis missing values were
replaced with the median gene expression value of 0. The samples classified as
PAM50 basal-like were stratified on expression of ID4, and the top 25% (ID4hi)
and bottom 25% (ID4lo) expressing samples were selected (see Supplementary Data
3 for a list of the stratified patient sample barcodes and ID4 expression level).
Analysis of TCGA expression data. Differential gene expression between the
ID4hi and ID4lo basal-like patient groups was assessed for each gene using an
empirical Bayes, moderated t-statistic implemented in Limma62 via the limmaGP
tool in GenePattern.
GSEA63 was run with the GenePattern tool GSEApreranked using a ranked list
of the Limma moderated t-statistics against the curated gene sets from version 4.0
of the Molecular Signatures Database63. The minimum and maximum gene-set
sizes used were 15 and 500, respectively, with 1,000 permutations performed.
All analyses were performed using GenePattern64 software modules, which are
available at http://pwbc.garvan.unsw.edu.au/gp/.
Subtype expression signature analysis. Subtype SES analysis was carried out
using the TCGA Agilent mRNA microarray expression data and the mammary
cell-lineage-specific gene sets as described in ref. 29.
Specifically, an expression signature score was calculated for each of the 522
samples identified from the TCGA Agilent mRNA microarray expression data set.
A higher score indicates that the breast cancer sample is more positively correlated
with the mammary cell-lineage gene signature.
Subtype expression signature scores, s, were calculated as follows,
s ¼
P
g
xgyg
P
g
xg




where the sum is over all genes, g, in the mammary cell-lineage-derived expression
signature gene sets, xg is the log-fold change for that gene in the cell lineage
signature and yg is the log2 expression for the same gene in the TCGA sample.
Non-matching gene symbols were discarded and for each gene only the probe with
highest expression level was used.
The TCGA samples were then stratified into PAM50-predicted
molecular subtypes and the ID4hi- and ID4lo-expressing basal-like subsets
(as described above). P values were calculated between each sample set using
the Wilcoxon–Mann–Whitney test.
Analysis of ID4 protein expression in breast cancer subtypes. Samples were
obtained from the Australian Breast Cancer Tissue Bank and had been classified as
luminal A, luminal B, Her2-positive or triple negative based on expression of ER,
PR and Her2. A separate BLBC cohort used for survival analysis was classified
based on lack of ER, PR and Her2 expression but positive staining for EGFR,
Table 2 | QRT–PCR assays used for gene expression studies.
Gene TaqMan assay ID
Mouse Id4 Mm00499701_m1
Mouse Krt8 Mm00835759_m1
Mouse Elf-5 Mm00468732_m1
Mouse b-casein Mm00839664_m1
Mouse Brca1 Mm00515386_m1
Mouse Notch1 Mm00435249_m1
Mouse Hey1 Mm00468865_m1
Mouse Jag1 Mm00496902_m1
Mouse Krt14 Mm00516876_m1
Mouse b-actin 4352341E
Mouse Gapdh 4352339E
Human ID4 Hs02912975_g1
Human RPLP0 Hs99999902_m1
Human GAPDH 4326317E
QRT–PCR, quantitative reverse transcription–PCR.
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cytokeratin 5/6 or cytokeratin 14, and stained for Id4 using a rabbit monoclonal
antibody (Biocheck). IHC was scored by a trained pathologist blinded to the
identity of specimens. The H-score was determined by multiplying the staining
intensity (0–3) with the percentage of positive nuclei.
Analysis of the NKI-295 data set. Data were taken from array profiling of the
NKI-295 breast cancer cohort65, and basal breast cancers were identified using a
single sample predictor66. Samples were allocated into ID4 high versus low using
mixture modelling and the association with overall survival analysed.
Single-cell analysis. Comma-Db cells were seeded at 8 104 cells per well into six-
well plates, 96 h later (day 0) the media was removed, cells were washed twice with
PBS and media was replaced without mEGF. Day 2, cells were collected in a single-
cell suspension of a concentration of 250Kml 1 in native medium. Using the C1
Single-Cell Auto Prep System (Fluidigm) the cells were loaded onto a C1 Single-Cell
Auto Prep Integrated Fluidics Circuit (IFC) and captured and stained for viability
with the LIVE/DEAD Cell Viability/Cytotoxicity Kit (Invitrogen). Subsequent cell
lysis, reverse transcription and 18 cycles of preamplification using a pooled primer
mix of all target gene F/R primers was performed on the microfluidic device. Tube
control samples of 1,000 cells were processed off-chip in parallel as positive controls.
Amplified cDNA libraries from each single cell on the IFC were harvested in 3ml and
diluted in 25ml of C1 DNA dilution buffer. The diluted cDNA was then mixed with
TaqMan Gene Expression MasterMix (Life Technologies) and loading reagents
(Fluidigm) and introduced onto a 96.96 gene expression Dynamic Array IFC
(Fluidigm) for quantitative (q)RT–PCR analysis. The same TaqMan assays used in
the single-cell preamplification were used for qRT–PCR (Supplementary Data 1).
Samples and assays were mixed in a 96 96-format, amplified and measured for
fluorescence using a BioMark HD genetic analysis system (Fluidigm).
The two data files were independently loaded into the Fluidigm Real-Time PCR
Analysis software (v 4.0.1) and then manually edited to remove any failed
reactions. As the two data sets had been run on separate chips, a normalization step
was required to ensure the data could be combined without bias. This was achieved
by performing independent normalization calculations for each cell using the
arithmetic mean of the three housekeeping genes (Gapdh, Hprt and Rplp0). Once
combined, the Id4 high and low cells were identified by selecting the upper and
lower quartiles of the normalized cycle threshold (CT) values and labelled as such.
The edited file was then analysed using the SINGuLAR software (v 2.0.2, (http://
www.fluidigm.com/singular-analysis-toolset.html), whereby outlier samples were
identified, before principal component analysis (PCA), ANOVA and unsupervised
clustering analysis were performed.
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